SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19
Study sponsor: Atea Pharmaceuticals, Inc. · AVIR
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-04-25Actual
Enrollment · participants2285Actual
Source updated2025-06-13Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.